<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathobiology of Burkitt lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathobiology of Burkitt lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathobiology of Burkitt lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer R Brown, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Burkitt lymphoma (BL) is a highly aggressive B cell neoplasm characterized by the translocation and deregulation of the <em>MYC</em> gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features among the three forms. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Clinical features'</a>.)</p><p>Current lymphoma classification systems consider BL with tissue-only disease and BL with peripheral blood involvement different manifestations of the same disease [<a href="#rid1">1,2</a>]. Classification of BL and other lymphomas is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Lymphoid neoplasms'</a>.)</p><p>The pathogenesis of BL is discussed in this topic. </p><p>Clinical manifestations, diagnosis, and treatment of BL are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4734.html" rel="external">"Treatment of Burkitt leukemia/lymphoma in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CELL OF ORIGIN</span><span class="headingEndMark"> — </span>BL is derived from germinal or post-germinal center B cells. The germinal or post-germinal center ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes (<em>IgV</em>), which serve as a marker of germinal center transit, as well as the tumor cell immunophenotype. Some studies have demonstrated ongoing somatic mutation, a process that is normally restricted to germinal center B cells. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a> and  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Other genetic abnormalities'</a>.)</p><p>The different clinical subtypes of BL (ie, endemic, nonendemic, and immunodeficiency-related) likely arise from B cells at different stages of development. Specifically, Epstein-Barr virus (EBV)-negative BLs show a low level of somatic hypermutation of their variable region heavy chain genes and no signs of antigen selection, whereas EBV-positive (generally endemic or AIDS-related) BLs have significantly higher levels of somatic hypermutation and evidence of antigen selection [<a href="#rid3">3</a>]. These findings suggest that EBV-negative BL may arise from an early centroblast, while EBV-positive BL may arise from a memory B cell or late germinal center B cell. This difference in cell of origin may also relate to the observed difference in <em>MYC</em> translocation breakpoints described below. Despite these differences, these clinical subtypes may have a common pathogenesis, based on similarities in gene expression [<a href="#rid4">4</a>]. (See <a class="local">'Chromosomal translocations'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H4"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The development of BL is dependent on the constitutive expression of the <em>MYC</em> gene located at chromosome 8q24, which encodes the MYC protein transcription factor. MYC modulates the expression of target genes that regulate many cellular processes, including cell growth, division, death, metabolism, adhesion, and motility [<a href="#rid5">5,6</a>]. Cells can generate high levels of MYC protein through various mechanisms, as described in the sections below.</p><p>The vast majority of BL have rearrangements of the <em>MYC</em> gene. However, additional factors beyond <em>MYC</em> translocation must occur for the development of BL. In support of this idea, a small percentage of HIV-positive persons and healthy controls have <em>MYC</em> translocations in B lymphocytes isolated from enlarged lymph nodes, a finding that does not appear to predict the later emergence of lymphoma [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">MYC in normal cells</span><span class="headingEndMark"> — </span>The <em>MYC</em> gene encodes a ubiquitously expressed nuclear phosphoprotein that functions as a pleiotropic transcriptional regulator of cell proliferation, differentiation, and apoptosis [<a href="#rid5">5</a>]. In vivo, MYC is found mainly in heterodimeric complexes with the related protein MAX; these heterodimers bind to the "E box consensus sequence" and directly activate transcription. The MYC-MAX interaction is required for MYC to stimulate transcription and cell proliferation [<a href="#rid8">8-10</a>]. Remarkably, there appear to be thousands of bona fide MYC/MAX binding sites in the genome that permit MYC to regulate the expression of numerous genes, leading to the idea that it may be better viewed as a global regulator of chromatin and gene expression than as a conventional transcription factor [<a href="#rid11">11,12</a>]. As a result, cells that express high levels of MYC produce far more ribonucleic acid (RNA) per cell than those that do not [<a href="#rid13">13</a>]. The net effect of this enhanced gene expression is to support both cell cycle progression and Warburg metabolism, which act together to maximize cell growth and proliferation [<a href="#rid14">14</a>].</p><p>MYC activity is normally regulated by the amount of MAX available to form MYC-MAX heterodimers and by competition from complexes formed by MAX with other proteins. MAX can form homodimers (MAX-MAX) and heterodimers with MAD family proteins (ie, MNT, MGA) that are negative regulators of transcription and block MYC-dependent transformation [<a href="#rid15">15,16</a>]. It is postulated that MAD-MAX or MNT-MAX heterodimers inhibit MYC function by either sequestering MAX and preventing the formation of MYC/MAX heterodimers or by competing with MYC/MAX heterodimers for binding to the same target sites. Upregulation of MYC favors MYC-MAX over MNT-MAX complexes at the promoters of target genes, thereby promoting cell cycle progression, while overexpression of MNT inhibits MYC-induced cell cycle entry, consistent with a hypothesis of competitive binding to MAX [<a href="#rid17">17</a>]. In non-Hodgkin lymphomas carrying <em>MYC</em> translocations, it is likely that constitutive expression of MYC increases the ratio of MYC/MAX complexes relative to inhibitory heterodimers, leading to upregulation of a program of gene expression that promotes growth.</p><p>The role of MYC in normal germinal center B cells was initially obscure, as most germinal center B cells exhibit low levels of MYC expression. However, conditional <em>Myc</em> knockout mice have established that MYC is essential for the initial proliferative burst that occurs following T cell-dependent antigen-mediated activation of B cells and for the establishment of germinal centers [<a href="#rid18">18,19</a>]. Shortly after entry into germinal centers, antigen-activated B cells downregulate MYC, but a subset of cells re-express MYC, which may contribute to the process of proliferation-associated somatic hypermutation of germinal center B cells.</p><p class="headingAnchor" id="H6"><span class="h2">MYC overexpression</span><span class="headingEndMark"> — </span>BL is characterized by inappropriately high levels of MYC expression, which may occur through at least one of the following mechanisms [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chromosomal translocations place <em>MYC</em> under the control of immunoglobulin gene enhancers that are constitutively active in mature B cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5' regulatory regions normally flanking the <em>MYC</em> gene body are mutated or removed as a direct result of the translocation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations of the <em>MYC</em> coding sequence result in amino acid substitutions that stabilize MYC protein by decreasing its proteosome-mediated degradation, thereby increasing its half-life.</p><p></p><p>Substantial experimental evidence has shown that constitutive expression of MYC influences the growth of B cells in vitro and in vivo, consistent with a role in B cell lymphomagenesis. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In vitro, the expression of a <em>MYC</em> gene in Epstein-Barr virus (EBV)-immortalized human B cells leads to their malignant transformation [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vivo, transgenic overexpression of <em>MYC</em> in B cell lineage cells in mice leads to the development of B cell malignancy [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gene expression profiling of primary BL has confirmed the overexpression of MYC target genes identified in experimental models [<a href="#rid22">22,23</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Chromosomal translocations</span><span class="headingEndMark"> — </span>In virtually all cases, BL is associated with a translocation between the long arm of chromosome 8, the site of the <em>MYC</em> gene (8q24), and one of three Ig genes [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The Ig heavy chain gene on chromosome 14 – Resulting in the t(8;14)(q24;q32) found in 80 percent of BL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The kappa light chain gene on chromosome 2 – Resulting in the t(2;8)(p11;q24) found in 15 percent of BL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lambda light chain gene on chromosome 22 – Resulting in the t(8;22)(q24;q11) found in 5 percent of BL.</p><p></p><p>The common effect of these translocations is that the translocated <em>MYC</em> allele is expressed constitutively in tumor cells, as opposed to the tight regulation of MYC levels in normal B cells [<a href="#rid25">25</a>]. (See <a class="local">'MYC in normal cells'</a> above.)</p><p>Although fairly homogeneous at the microscopic level, these translocations display a high degree of molecular heterogeneity. The specific gene breakpoint sites vary not only by translocation but also by clinical context (ie, endemic versus sporadic cases):</p><p class="bulletIndent1"><span class="glyph">●</span>The breakpoint sites on chromosome 8 found in t(8;14) are located 5' and centromeric to <em>MYC</em>, whereas the sites found in t(2;8) and t(8;22) map 3' to <em>MYC</em> [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In endemic (African) cases, the breakpoint on chromosome 14 involves the heavy chain joining region and the breakpoint in chromosome 8 usually lies adjacent to <em>MYC</em>, while in non-endemic cases, the breakpoint on chromosome 14 involves the heavy chain class-switch region and the breakpoint in chromosome 8 often lies in intron 1 of <em>MYC</em> [<a href="#rid26">26,27</a>]. </p><p></p><p>This molecular heterogeneity precludes the development of sensitive polymerase chain reaction (PCR) based testing for these translocations. Instead, these translocations are identified either by karyotyping of metaphase chromosomes or by fluorescence in situ hybridization (FISH).</p><p>Work using mouse models has shed light on the possible mechanisms that lead to <em>MYC</em> translocations. Translocations involving the class-switch region of the immunoglobulin heavy chain gene and <em>MYC</em> occur with surprisingly high frequency in activated B cells undergoing class-switch recombination. These "mistakes" occur during the recombination event that allows B cells to switch from the expression of IgM to the expression of other immunoglobulin types and require the enzyme activation-induced cytidine deaminase (AID) [<a href="#rid28">28</a>], which is an essential co-factor for normal class-switch recombination. In further support of a role for AID in chromosomal rearrangements that lead to lymphomagenesis, infection of mice with malaria (a risk factor for human endemic BL) provokes sustained expansion of AID-expressing germinal center B cells and increases the development of aggressive B cell lymphomas with chromosomal rearrangements bearing the molecular signatures of AID-mediated deoxyribonucleic acid (DNA) damage [<a href="#rid29">29</a>].</p><p>Other work has shown that <em>MYC</em> tends to lie in close proximity to the immunoglobulin heavy chain locus in the nuclei of B cells, which may explain in part why <em>MYC</em> is often involved in such translocations. It is hypothesized that most cells bearing these translocations die rapidly, as unbridled MYC expression is a potent inducer of apoptosis (programmed cell death) in normal cells. How BL cells escape this fate is largely unknown; in some tumors, however, loss of TP53 function may abrogate MYC-induced apoptosis. (See <a class="local">'Other genetic lesions'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h3">Other mechanisms</span><span class="headingEndMark"> — </span>As mentioned above, up to 5 percent of tumors with features that are otherwise typical of BL lack <em>MYC</em> rearrangements. Other mechanisms leading to the increased expression of <em>MYC</em> include interference with the 5' regulatory regions and/or stabilization of the protein product.</p><p>5' regulatory regions normally present within the <em>MYC</em> DNA sequence can be mutated or moved away from <em>MYC</em> as a direct result of the translocation. Release of <em>MYC</em> from normal regulation can result in increased expression. The <em>MYC</em> first exon/first intron border, where <em>MYC</em> regulatory sequences are located, can be either decapitated by the translocations described in the section above or undergo mutation in translocated alleles [<a href="#rid24">24,30</a>].</p><p>Alternatively, the transactivation domain of MYC (encoded in exon 2) can acquire mutations that interfere with modulation of MYC activity by p107 [<a href="#rid31">31,32</a>]. Other mutations may stabilize MYC by decreasing proteasomal degradation.</p><p class="headingAnchor" id="H1557363"><span class="h2">Consequences of MYC overexpression</span><span class="headingEndMark"> — </span>BL may be the fastest growing human cancer and MYC overexpression is believed to be responsible for many of the alterations that support the rapid growth of BL tumors cells [<a href="#rid33">33</a>]. Included among these MYC-dependent activities are:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased glucose utilization and a switch to so-called Warburg metabolism, in which cells mainly rely on glycolysis for ATP production instead of oxidative phosphorylation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased glutamine metabolism, which creates metabolic intermediates that are needed for membrane biogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation of rRNA expression and ribosome biogenesis, leading to increased protein synthesis.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Other genetic lesions</span><span class="headingEndMark"> — </span>In addition to the presence of <em>MYC</em> translocations in the vast majority of BL cases, most tumors contain additional chromosomal abnormalities, the molecular implications of which are poorly understood [<a href="#rid34">34</a>]. Of interest, BL cases appear to have fewer additional genetic lesions than DLBCL or unclassifiable aggressive B cell lymphomas [<a href="#rid35">35</a>].</p><p>Other pathogenic mutations in BL have emerged from genomic sequencing:</p><p class="bulletIndent1"><span class="glyph">●</span>A study that reported whole genome sequencing of 101 tumors, which included all three categories of BL (ie, endemic, sporadic, immunodeficiency associated) reported likely driver mutations in 72 genes; these alterations involved both coding and non-coding regions [<a href="#rid36">36</a>]. In vitro assays were used to confirm a functional role for a subset of these genes (eg, <em>MYC</em>, <em>IGLL5</em>, <em>BACH2</em>, <em>ID3</em>, and <em>BTG2</em>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, high-throughput RNA sequencing and RNA interference screening identified recurrent mutations in components of the p53, cyclin D3/CDK6, PI(3) kinase, and tonic BCR signaling pathways [<a href="#rid37">37</a>]. Approximately 70 percent of sporadic BL cases had mutations in <em>TCF3</em> or <em>ID3</em>. Mutations in <em>CCND3</em> (a gene encoding cyclin D3, a key regulator of cell cycle progression) were present in 38 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, whole genome sequencing of BL tumor tissue and germline tissue from the same individual identified mutations of potential interest that were further evaluated with exome sequencing of 59 BL cases and 94 DLBCL cases [<a href="#rid38">38</a>]. Mutations in <em>ID3</em> were identified in 34 percent of BL but were not present in DLBCL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a third study, whole genome and transcriptome sequencing of four BL cases identified seven recurrently mutated genes [<a href="#rid39">39</a>]. Further evaluation of these genes in an extension cohort demonstrated <em>ID3</em> mutations in 36 of 53 (68 percent) of patients with BL but only 6 of 47 (13 percent) of other B cell lymphomas with <em>Ig</em>-<em>MYC</em> translocation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Burkitt Lymphoma Genome Sequencing Project employs whole genome sequencing coupled with transcriptome analyses in an effort to comprehensively characterize the genetics of BL [<a href="#rid40">40</a>]. This ongoing work has identified 22 genes with mutations that are deemed to be significant, as judged by their presence in multiple tumors and their likely disruptive effects on gene function. Newly identified mutated genes include <em>DDX3X</em> (which encodes a putative RNA helicase linked to cell cycle progression) and a number of chromatin factors, including chromatin remodeling factors (<em>ARID1A</em>), chromatin "writers" (<em>KMT2D</em>), and even histones (<em>HIST1H1E</em>). How perturbation of these factors contribute to BL pathobiology remains to be determined.</p><p></p><p>A common theme emerging from these studies is the frequent occurrence in BL of loss of function mutations in <em>ID3</em> and gain of function mutations in <em>TCF3</em>, which encodes an E-box type transcription factor previously known as E2A that has important roles in lymphoid development. TCF3 appears to stimulate survival through the BCR/PI3K signaling pathway, which upregulates <em>CCND3</em> (cyclin D3) [<a href="#rid41">41</a>]. Normally, TCF3 also induces its own inhibitor (ID3), but this negative feedback loop is broken in BL by mutations that activate TCF3 and inactivate ID3. TCF3 appears to augment B cell receptor signaling, thereby enhancing pro-survival signaling mediated through the PI-3K pathway [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H12461909"><span class="h2">Other tumors with MYC translocations</span><span class="headingEndMark"> — </span>Other lymphoid tumors may have <em>MYC</em> translocations similar or identical to those found in BL, including diffuse large B cell lymphoma, multiple myeloma, and a subset of unclassifiable B cell lymphomas with some features of BL. In several studies of the latter tumors, cases with "Burkitt-like" features frequently had dual MYC and B cell leukemia/lymphoma 2 (<em>BCL2</em>) translocations (ie, "double hit" lymphomas) and were associated with an extremely poor clinical outcome [<a href="#rid42">42,43</a>]. Another study found that these "double hit" lymphomas could be distinguished from BL by their expression of BCL-2, expression of IRF4/MUM1, a Ki-67 staining fraction &lt;95 percent, and the absence of Epstein-Barr virus [<a href="#rid44">44</a>]. Many of these cases may represent "transformed" follicular lymphomas, in which the <em>MYC</em> translocation is acquired as a secondary event. (See  <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">"Pathobiology of follicular lymphoma", section on 'Translocations involving BCL-2'</a>.)</p><p class="headingAnchor" id="H691349484"><span class="h2">Other Burkitt-like tumors that lack MYC translocations</span><span class="headingEndMark"> — </span>The 2016 World Health Organization (WHO) classification of lymphoid neoplasms includes the provisional entity Burkitt-like lymphoma with 11q aberration [<a href="#rid45">45</a>]. These tumors lack <em>MYC</em> translocations, tend to occur in children and young adults, and have a gene expression profile and an immunophenotype that resemble those seen in BL. However, Burkitt-like lymphoma with 11q aberration has lower levels of <em>MYC</em> expression and appears to lack mutations in <em>TCF3</em> and <em>ID3</em> [<a href="#rid46">46</a>], indicating that it is genetically distinct from BL. Other tumors resembling BL that lack <em>MYC</em> rearrangements and 11q aberrations are best considered variants of diffuse large B-cell lymphoma or high-grade B-cell lymphoma, not otherwise specified, per the WHO classification [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H10"><span class="h2">Infections</span></p><p class="headingAnchor" id="H13168920"><span class="h3">General</span><span class="headingEndMark"> — </span>Chronic EBV infection appears to play a role in virtually all cases of endemic (African) BL and a minority of sporadic and immunodeficiency-associated BL. However, data suggest that EBV infection alone cannot account for the development of endemic BL and that the etiology is likely polymicrobial [<a href="#rid47">47</a>].</p><p>Patients with some other infections are more likely to have a persistent acute phase of initial EBV infection. This prolonged acute phase with its associated B cell expansion may increase the likelihood of acquisition of translocations involving the <em>MYC</em> locus. Proposed organisms associated with persistent EBV infection and BL development include HIV, malaria, and arboviruses [<a href="#rid48">48</a>]. The specific role of these organisms in the pathogenesis of BL remains to be determined.</p><p>Initial epidemiologic data demonstrated a high incidence of both <em>Plasmodium falciparum</em> malaria and endemic BL in equatorial Africa and Papua New Guinea [<a href="#rid49">49,50</a>]. Further evidence came from a study that demonstrated that, when compared with age-, sex-, and location-matched controls, cases of childhood endemic BL were more likely to have serologic evidence of a recent malaria infection (anti-HRP-II antibodies) and less likely to have serologic evidence of a long-term malaria infection (anti-SE36 antibodies) [<a href="#rid51">51</a>]. </p><p>Plausible explanations directly linking falciparum malaria to BL have emerged from several studies. Isolation of tonsillar germinal center B cells from individuals who are chronically infected with <em>P. falciparum</em> reveal an increase in cells expressing activation-induced cytosine deaminase (AID), an enzyme that may cause DNA damage that can lead to chromosomal translocations, including <em>MYC</em> translocations. Furthermore, a higher incidence of EBV-positivity was observed in germinal center B cells isolated from individuals with chronic <em>P. falciparum</em> infections [<a href="#rid52">52</a>]<em>.</em> Mouse models using recurrent <em>P. chabaudi</em> infection demonstrated expansion of germinal center B cells expressing AID and development of aggressive lymphomas in a p53-deficient background [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Epstein-Barr virus (EBV) infection</span><span class="headingEndMark"> — </span>Monoclonal EBV infection is present in virtually all cases of endemic BL, approximately 30 percent of sporadic BL, and 40 percent of immunodeficiency-associated BL. The pathobiologic role of EBV infection in the development of BL is poorly understood.</p><p>One hypothesis is that EBV infection stimulates B cell expansion during which process translocations may occur, leading to the overexpression of <em>MYC</em>. Once BL emerges, the EBV infection is thought to have little effect on tumor maintenance. Of interest, EBV infection in BL displays a particular latent infection phenotype characterized by the lack of expression of the EBV transforming proteins LMP-1 and EBNA-2. (See  <a class="medical medical_review" href="/z/d/html/8276.html" rel="external">"Virology of Epstein-Barr virus", section on 'Transformation and latent proteins'</a>.)</p><p>Whole-genome analysis of 106 cases of endemic and sporadic BL reported that, compared with EBV-negative tumors, EBV-positive tumors had a striking increase in somatic hypermutation and fewer driver mutations (eg, <em>CCND3</em> mutations) [<a href="#rid53">53</a>]. The increase in somatic hypermutation in EBV-positive cases is consistent with prior work showing that EBV infection increases the expression of activation-induced cytosine deaminase in B cells [<a href="#rid54">54</a>]. These distinctions may also be related to different cells of origin for EBV-positive and EBV-negative BLs. (See <a class="local">'Cell of origin'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Burkitt lymphoma (BL) refers to a group of highly aggressive B cell neoplasms with three distinct clinical forms: endemic, sporadic, and immunodeficiency associated. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell of origin</strong> – BL is derived from germinal or post-germinal center B cells. (See <a class="local">'Cell of origin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of MYC overexpression</strong> – BL development is dependent on constitutive expression of the MYC transcription factor, which is encoded by the <em>MYC</em> gene, located at chromosome 8q24. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1">Tumor cells maintain high expression of MYC through various mechanisms (see <a class="local">'MYC overexpression'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chromosomal translocations</strong> – BL is generally associated with translocation between the long arm of chromosome 8 (the <em>MYC</em> locus) and one of three immunoglobulin (Ig) genes that place the DNA coding sequences for <em>MYC</em> under the control of Ig gene enhancers that are constitutively active in mature B cells. The translocations include t(8;14), t(2;8), and t(8;22). (See <a class="local">'Chromosomal translocations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other mechanisms</strong> – In a small percentage of cases, the <em>MYC</em> DNA sequence can be mutated or moved in ways that increase MYC. Examples include increased <em>MYC</em> gene expression and mutations of the coding sequence that modulate MYC activity by increased half-life of the protein product or modulation of interaction with p107. (See <a class="local">'Other mechanisms'</a> above.)</p><p></p><p class="bulletIndent1">Inherent genomic instability of germinal center B cells appears to contribute to MYC rearrangements in BL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consequences of increased MYC</strong> – MYC modulates expression of target genes that regulate many cellular processes, including cell growth, division, and death. Rapid growth is aided by the alteration of MYC targets, including increased glycolysis for ATP production, instead of oxidative phosphorylation (the Warburg effect); increased glutamine metabolism, which creates metabolic intermediates needed for membrane biogenesis; and increased protein synthesis, in association with upregulation of rRNA expression and ribosome biogenesis. (See <a class="local">'Consequences of MYC overexpression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV) infection</strong> – Chronic EBV infection plays a role in virtually all cases of endemic (African) BL and in a minority of sporadic and immunodeficiency-associated BL. (See <a class="local">'Infections'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106:1031.</a></li><li><a class="nounderline abstract_t">Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011; 117:3596.</a></li><li><a class="nounderline abstract_t">Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707.</a></li><li><a class="nounderline abstract_t">Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010; 149:484.</a></li><li><a class="nounderline abstract_t">Müller JR, Janz S, Goedert JJ, et al. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci U S A 1995; 92:6577.</a></li><li><a class="nounderline abstract_t">Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251:1211.</a></li><li><a class="nounderline abstract_t">Blackwood EM, Lüscher B, Eisenman RN. Myc and Max associate in vivo. Genes Dev 1992; 6:71.</a></li><li><a class="nounderline abstract_t">Gu W, Cechova K, Tassi V, Dalla-Favera R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc Natl Acad Sci U S A 1993; 90:2935.</a></li><li><a class="nounderline abstract_t">Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755.</a></li><li><a class="nounderline abstract_t">Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151:68.</a></li><li><a class="nounderline abstract_t">Lovén J, Orlando DA, Sigova AA, et al. Revisiting global gene expression analysis. Cell 2012; 151:476.</a></li><li><a class="nounderline abstract_t">Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297.</a></li><li><a class="nounderline abstract_t">Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72:211.</a></li><li><a class="nounderline abstract_t">Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72:223.</a></li><li><a class="nounderline abstract_t">Walker W, Zhou ZQ, Ota S, et al. Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 2005; 169:405.</a></li><li><a class="nounderline abstract_t">Calado DP, Sasaki Y, Godinho SA, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 2012; 13:1092.</a></li><li><a class="nounderline abstract_t">Stamm O, Latscha U, Janecek P, Campana A. Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp. Am J Obstet Gynecol 1976; 124:193.</a></li><li><a class="nounderline abstract_t">Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987; 49:161.</a></li><li><a class="nounderline abstract_t">Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533.</a></li><li><a class="nounderline abstract_t">Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.</a></li><li><a class="nounderline abstract_t">Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.</a></li><li><a class="nounderline abstract_t">Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824.</a></li><li><a class="nounderline abstract_t">ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983; 222:390.</a></li><li><a class="nounderline abstract_t">Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986; 83:2984.</a></li><li><a class="nounderline abstract_t">Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1988; 85:2748.</a></li><li><a class="nounderline abstract_t">Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105.</a></li><li><a class="nounderline abstract_t">Robbiani DF, Deroubaix S, Feldhahn N, et al. Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell 2015; 162:727.</a></li><li><a class="nounderline abstract_t">Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987; 238:1272.</a></li><li><a class="nounderline abstract_t">Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5:56.</a></li><li><a class="nounderline abstract_t">Gu W, Bhatia K, Magrath IT, et al. Binding and suppression of the Myc transcriptional activation domain by p107. Science 1994; 264:251.</a></li><li><a class="nounderline abstract_t">Dang CV. MYC on the path to cancer. Cell 2012; 149:22.</a></li><li><a class="nounderline abstract_t">Toujani S, Dessen P, Ithzar N, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 2009; 4:e7089.</a></li><li><a class="nounderline abstract_t">Seegmiller AC, Garcia R, Huang R, et al. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 2010; 23:909.</a></li><li><a class="nounderline abstract_t">Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 2019; 134:1598.</a></li><li><a class="nounderline abstract_t">Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490:116.</a></li><li><a class="nounderline abstract_t">Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44:1321.</a></li><li><a class="nounderline abstract_t">Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44:1316.</a></li><li><a class="nounderline abstract_t">Grande BM, Gerhard DS, Griner NB, et al. Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma. Blood (ASH Annual Meeting Abstracts) 2017; 130:39.</a></li><li><a class="nounderline abstract_t">Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012; 22:167.</a></li><li><a class="nounderline abstract_t">Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17:1558.</a></li><li><a class="nounderline abstract_t">Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273.</a></li><li><a class="nounderline abstract_t">Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 2019; 104:1822.</a></li><li><a class="nounderline abstract_t">Chene A, Donati D, Orem J, et al. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol 2009; 19:411.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol 2008; 9:683.</a></li><li><a class="nounderline abstract_t">Morrow RH Jr. Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma. IARC Sci Publ 1985; :177.</a></li><li><a class="nounderline abstract_t">Aka P, Vila MC, Jariwala A, et al. Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response. Blood 2013; 122:629.</a></li><li><a class="nounderline abstract_t">Torgbor C, Awuah P, Deitsch K, et al. A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog 2014; 10:e1004170.</a></li><li><a class="nounderline abstract_t">Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 2019; 133:1313.</a></li><li><a class="nounderline abstract_t">Kalchschmidt JS, Bashford-Rogers R, Paschos K, et al. Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med 2016; 213:921.</a></li></ol></div><div id="topicVersionRevision">Topic 4723 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840698" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245480" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054444" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Molecular biology of Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346013" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Advances in the understanding of MYC-induced lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604036" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006410" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730411" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myc and Max associate in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385351" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Opposite regulation of gene transcription and cell proliferation by c-Myc and Max.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923074" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Myc's broad reach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021216" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23101621" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Revisiting global gene expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22439925" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425218" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425219" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866886" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mnt-Max to Myc-Max complex switching regulates cell cycle entry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001146" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3032447" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3906410" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760443" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Molecular diagnosis of Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760442" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6961453" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6414084" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3458257" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2833750" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16400328" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Role of genomic instability and p53 in AID-induced c-myc-Igh translocations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26276629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3685977" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8220424" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8146655" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Binding and suppression of the Myc transcriptional activation domain by p107.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464321" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : MYC on the path to cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19759907" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348878" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558468" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The whole-genome landscape of Burkitt lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22885699" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23143597" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The genetic landscape of mutations in Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23143595" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897848" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334544" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597184" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118770" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118770" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30733272" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897039" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897039" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598933" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Part I: Cancer in Indigenous Africans--burden, distribution, and trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905588" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645841" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24874410" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617194" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27217538" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
